Sundrug CoTSE:9989 +0.64%82 EBITDA Margin % is 2.05% as of Dec. 2025, which is 72% below its 10-year median of 7.44. GuruFocus rates TSE:9989 with a GF Score™ of 82/100 and a GF Value™ of 円4,719.27 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 668 Healthcare Providers & Services companies, Sundrug Co ranks worse than 57.78% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sundrug Co's EBITDA for the
three
months ended in Dec. 2025 was 円4,446 Mil. Sundrug Co's Revenue for the
three
months ended in Dec. 2025 was 円217,270 Mil. Therefore, Sundrug Co's EBITDA margin for the quarter that ended in Dec. 2025 was 2.05%.
Sundrug Co (TSE:9989) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sundrug Co EBITDA Margin % Related Terms
Sundrug Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sundrug Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Sundrug Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sundrug Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sundrug Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sundrug Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sundrug Co (TSE:9989) has a EBITDA Margin % of 2.05% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sundrug Co and its competitors. This is 72% below median its historical median of 7.44. Over the past decade, Sundrug Co's EBITDA Margin % has ranged from 6.92 to 7.87. According to the industry distribution chart, Sundrug Co ranks #386 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 57.8%.
Is Sundrug Co's EBITDA Margin % too high?
Sundrug Co's current EBITDA Margin % of 2.05% is 72% below median its 10-year median of 7.44. Over the past 10 years, this metric has ranged from a low of 6.92 to a high of 7.87. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Sundrug Co's value of 2.05% is 79.9% below this industry median. Based on the distribution chart, Sundrug Co ranks #386 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sundrug Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sundrug Co's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sundrug Co ranks #386 out of 668 companies for EBITDA Margin %. This places Sundrug Co in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Sundrug Co's value of 2.05% is 79.9% below this benchmark. Historically, Sundrug Co's own EBITDA Margin % has ranged from 6.92 to 7.87 over the past decade. While the company's 10-year median is 7.44 vs. the industry median of 10.21, Sundrug Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sundrug Co's current EBITDA Margin % of 2.05% is 79.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sundrug Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sundrug Co's current EBITDA Margin % is 2.05%, which is 72% below median its own 10-year median of 7.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sundrug Co stock overvalued right now?
Based on GuruFocus' analysis, Sundrug Co (TSE:9989) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,719.27, compared to a current price of 円3,792.00 — trading 19.6% below its estimated fair value. The current EBITDA Margin % is 2.05%, which is 72% below median its 10-year median of 7.44 and 79.9% below the Healthcare Providers & Services industry median of 10.21. Sundrug Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sundrug Co (TSE:9989), the current EBITDA Margin % is 2.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sundrug Co (TSE:9989) Overvalued in 2026?
Based on GuruFocus' analysis, Sundrug Co stock appears to be undervalued.
The current stock price of 円3,792.00 is trading 19.6% below its estimated GF Value™ of 円4,719.27.
GuruFocus considers Sundrug Co to be Modestly Undervalued.
Key valuation signals for TSE:9989:
EBITDA Margin %: 2.05% (72% below median its 10-year median of 7.44)
GF Value™: 円4,719.27 vs. price of 円3,792.00 (19.6% below fair value)
Industry Position: 79.9% below the Healthcare Providers & Services median (#386 of 668)
No single metric tells the full story. See the TSE:9989 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sundrug Co Ltd is a Japanese-based company engaged in the operation of drug stores and discount stores. The Group operates through two segments: the Drug Store Business, which mainly sells pharmaceuticals, cosmetics, and daily necessities, and the Discount Store Business, which mainly sells food products, household goods, and other related items. It generates the majority of its revenue from the Drugstore business segment.
82GF Score
Get the complete analysis for TSE:9989
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9989 has been successfully added to your 
